| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 12/02/2022 | 511.11% | HC Wainwright & Co. | → $11 | Initiates Coverage On | → Buy |
| 03/31/2022 | 566.67% | BMO Capital | $18 → $12 | Maintains | Outperform |
| 11/19/2021 | 900% | BMO Capital | → $18 | Initiates Coverage On | → Outperform |
| 08/23/2021 | 400% | UBS | → $9 | Initiates Coverage On | → Buy |
| 08/23/2021 | 1122.22% | Jefferies | → $22 | Initiates Coverage On | → Buy |
| 08/23/2021 | 733.33% | Credit Suisse | → $15 | Initiates Coverage On | → Outperform |
What is the target price for Candel Therapeutics (CADL)?
The latest price target for Candel Therapeutics (NASDAQ: CADL) was reported by HC Wainwright & Co. on December 2, 2022. The analyst firm set a price target for $11.00 expecting CADL to rise to within 12 months (a possible 511.11% upside). 2 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Candel Therapeutics (CADL)?
The latest analyst rating for Candel Therapeutics (NASDAQ: CADL) was provided by HC Wainwright & Co., and Candel Therapeutics initiated their buy rating.
When is the next analyst rating going to be posted or updated for Candel Therapeutics (CADL)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Candel Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Candel Therapeutics was filed on December 2, 2022 so you should expect the next rating to be made available sometime around December 2, 2023.
Is the Analyst Rating Candel Therapeutics (CADL) correct?
While ratings are subjective and will change, the latest Candel Therapeutics (CADL) rating was a initiated with a price target of $0.00 to $11.00. The current price Candel Therapeutics (CADL) is trading at is $1.80, which is within the analyst's predicted range.